NICE and NHS England launched a consultation in Autumn 2016 on changes proposed  to the arrangements for evaluating and funding drugs and other health technologies appraised through NICE’s Technology Appraisal (TA) and Highly Specialised Technologies (HST) programmes.

We argued that the NHS needs to become more adept at phasing in new treatments and technologies that are proven to be cost-effective, and disinvesting in outdated lower-value activities.

We also recognised that introducing new technologies can cause disruption to existing services but in times of financial constraint the need to encourage innovation, and shift resources to higher-value activities, is even more urgent.

Furthermore, we argued if the NHS has to prioritise new technologies in a period of financial constraint it should prioritise treatments and technologies by their relative cost-effectiveness, rather than their budgetary impact.

You might also like...

Press release

Contact tracing app threatens to exacerbate unequal risk of COVID-19

New polling data with Ipsos MORI reveal UK public’s awareness of and attitudes towards the planned...

Newsletter blog

How better health and care data can support the fight against COVID-19

Data is telling a horrifying story about the toll that the pandemic is taking. It’s also playing a...

Consultation response

‘For a greener NHS’ campaign

Health Foundation response to the NHS Net Zero Expert Panel consultation on how the NHS can continue...

Kjell-bubble-diagramArtboard 101

Work with us

We look for talented and passionate individuals as everyone at the Health Foundation has an important role to play.

View current vacancies
Artboard 101 copy 2

The Q community

Q is an initiative connecting people with improvement expertise across the UK.

Find out more